MeSH term
Frequency | Condition_Probility | Female | 348 | 0.0 |
Humans | 1197 | 0.0 |
Pregnancy | 30 | 0.0 |
Randomized Controlled Trials | 2 | 0.0 |
Antihypertensive Agents/*therapeutic use | 2 | 0.0 |
Animals | 249 | 0.0 |
Antibodies, Monoclonal/chemistry | 3 | 3.0 |
*Antigens, Neoplasm | 2 | 1.0 |
Immunohistochemistry | 68 | 0.0 |
Prognosis | 24 | 0.0 |
Recurrence | 12 | 0.0 |
Time Factors | 49 | 0.0 |
Cell Separation | 7 | 0.0 |
Dilazep/*pharmacology | 2 | 66.0 |
Gene Expression/drug effects | 13 | 1.0 |
Monocytes/*metabolism | 35 | 9.0 |
Platelet Aggregation Inhibitors/pharmacology | 3 | 4.0 |
RNA, Messenger/biosynthesis/genetics | 7 | 1.0 |
Research Support, Non-U.S. Gov't | 626 | 0.0 |
Thromboplastin/*biosynthesis/genetics | 42 | 87.0 |
Amino Acid Substitution | 4 | 0.0 |
Isoelectric Focusing | 19 | 3.0 |
Mutation, Missense | 2 | 0.0 |
Transferrin/*genetics/metabolism | 5 | 83.0 |
Phosphorylation | 13 | 0.0 |
Thromboplastin/*metabolism | 117 | 73.0 |
Tumor Necrosis Factor-alpha/pharmacology | 20 | 1.0 |
Adolescent | 71 | 0.0 |
Adult | 241 | 0.0 |
Aged | 153 | 0.0 |
Ferritin/*metabolism | 2 | 7.0 |
Male | 357 | 0.0 |
Middle Aged | 225 | 0.0 |
Reference Values | 29 | 0.0 |
Transferrin/*metabolism | 31 | 52.0 |
Child | 33 | 0.0 |
Diet Surveys | 2 | 8.0 |
Iron/blood | 4 | 4.0 |
Swine | 10 | 0.0 |
Thromboplastin/*antagonists & inhibitors | 11 | 52.0 |
Thrombosis/*prevention & control | 2 | 11.0 |
Cell Line | 59 | 0.0 |
DNA-Binding Proteins/metabolism | 6 | 0.0 |
Escherichia coli | 8 | 1.0 |
Lipopolysaccharides/*pharmacology | 21 | 4.0 |
*Protein-Serine-Threonine Kinases | 3 | 0.0 |
Proto-Oncogene Proteins/*metabolism | 2 | 0.0 |
Research Support, U.S. Gov't, P.H.S. | 289 | 0.0 |
Thromboplastin/genetics | 4 | 66.0 |
Transcription Factor AP-1/metabolism | 7 | 2.0 |
Transcription Factors/metabolism | 4 | 0.0 |
Transcription, Genetic/*drug effects | 6 | 1.0 |
Zinc Fingers | 2 | 0.0 |
Amino Acid Sequence | 54 | 0.0 |
Chromatography, Affinity | 11 | 1.0 |
Electrophoresis, Polyacrylamide Gel | 18 | 0.0 |
Molecular Sequence Data | 95 | 0.0 |
Recombinant Proteins/chemistry | 3 | 0.0 |
Analysis of Variance | 8 | 0.0 |
Base Sequence | 57 | 0.0 |
Blotting, Western | 29 | 0.0 |
Cells, Cultured | 192 | 1.0 |
Comparative Study | 134 | 0.0 |
Down-Regulation | 9 | 0.0 |
Leukocytes, Mononuclear | 3 | 6.0 |
Probability | 2 | 0.0 |
Pyridines/*pharmacology | 2 | 3.0 |
RNA, Messenger/analysis | 31 | 0.0 |
Reverse Transcriptase Polymerase Chain Reaction | 24 | 0.0 |
Sensitivity and Specificity | 24 | 0.0 |
Thromboplastin/biosynthesis/*drug effects | 3 | 100.0 |
Blood Transfusion | 2 | 1.0 |
Case-Control Studies | 32 | 0.0 |
Flow Cytometry | 32 | 0.0 |
Hemostatics/*metabolism | 2 | 50.0 |
Arteriosclerosis/*metabolism | 2 | 3.0 |
Cloning, Molecular | 19 | 0.0 |
DNA, Complementary/genetics | 4 | 0.0 |
English Abstract | 98 | 0.0 |
Gene Expression | 15 | 0.0 |
Mutation | 20 | 0.0 |
Thromboplastin/biosynthesis/genetics/*metabolism | 2 | 100.0 |
Coronary Arteriosclerosis/*blood | 2 | 14.0 |
Lipoproteins/*blood | 23 | 3.0 |
Blood Proteins/*metabolism | 3 | 1.0 |
In Vitro | 40 | 0.0 |
Kinetics | 97 | 1.0 |
Oxidation-Reduction | 9 | 0.0 |
Protein Binding | 55 | 0.0 |
Solutions | 6 | 3.0 |
Spectrophotometry, Atomic | 2 | 4.0 |
Acute-Phase Proteins/*physiology | 2 | 18.0 |
Blood Coagulation/*physiology | 23 | 19.0 |
Dimerization | 7 | 0.0 |
Endothelium, Vascular/chemistry/cytology/*metabolism | 2 | 66.0 |
*I-kappa B | 3 | 1.0 |
Interleukin-1/pharmacology | 10 | 1.0 |
Lipopolysaccharides/pharmacology | 51 | 5.0 |
NF-kappa B/metabolism | 20 | 2.0 |
Proto-Oncogene Proteins c-rel/metabolism | 3 | 30.0 |
RNA, Messenger/metabolism | 39 | 0.0 |
Thromboplastin/*biosynthesis/physiology | 4 | 100.0 |
Umbilical Veins | 35 | 8.0 |
Computer Systems | 2 | 3.0 |
Cytokines/biosynthesis | 2 | 0.0 |
Polymerase Chain Reaction | 27 | 0.0 |
Proto-Oncogene Proteins/metabolism | 4 | 0.0 |
Peptide Fragments/blood | 3 | 2.0 |
Prothrombin | 3 | 6.0 |
Severity of Illness Index | 13 | 1.0 |
Blood Coagulation/*drug effects | 22 | 17.0 |
Cattle | 29 | 1.0 |
Drug Interactions | 4 | 0.0 |
Factor IX/physiology | 2 | 100.0 |
Factor X/metabolism | 26 | 49.0 |
Prothrombin Time | 11 | 10.0 |
Rabbits | 37 | 1.0 |
Recombinant Proteins/pharmacology | 15 | 0.0 |
Thromboplastin/*pharmacology | 8 | 61.0 |
Anticoagulants/*pharmacology | 11 | 12.0 |
Fibrinolysis | 8 | 5.0 |
Gene Expression Regulation/drug effects | 18 | 2.0 |
Heparin/*pharmacology | 12 | 8.0 |
Lipoproteins/analysis | 4 | 17.0 |
Thromboplastin/analysis | 14 | 53.0 |
*Blood Coagulation | 26 | 12.0 |
Factor X/physiology | 3 | 42.0 |
Neoplasm Metastasis | 11 | 1.0 |
*Neoplasm Proteins | 3 | 0.0 |
Neoplasms/*blood/pathology | 2 | 25.0 |
Receptor, PAR-1 | 3 | 14.0 |
Receptor, PAR-2 | 3 | 27.0 |
Receptors, Thrombin/metabolism | 3 | 17.0 |
Up-Regulation | 15 | 0.0 |
*Bacterial Proteins | 2 | 1.0 |
Cell Membrane/metabolism | 19 | 1.0 |
Coagulants/*pharmacology | 2 | 50.0 |
Enzyme Inhibitors/pharmacology | 18 | 0.0 |
*Membrane Transport Proteins | 2 | 0.0 |
Mitogen-Activated Protein Kinases/antagonists & inhibitors/metabolism | 5 | 5.0 |
Protein Kinase Inhibitors | 2 | 1.0 |
RNA, Messenger/biosynthesis | 11 | 0.0 |
Reactive Oxygen Species/metabolism | 4 | 1.0 |
Thrombin/*pharmacology | 5 | 4.0 |
Thromboplastin/genetics/*metabolism | 25 | 86.0 |
Trans-Activation (Genetics)/drug effects | 5 | 2.0 |
p38 Mitogen-Activated Protein Kinases | 4 | 0.0 |
Aged, 80 and over | 36 | 0.0 |
Antigens, CD/metabolism | 3 | 0.0 |
Cytokines/*metabolism | 2 | 0.0 |
Endothelial Growth Factors/metabolism | 2 | 1.0 |
Endothelium, Vascular/*metabolism/pathology | 3 | 8.0 |
Factor VIII/metabolism | 3 | 3.0 |
Immunoenzyme Techniques | 12 | 0.0 |
Lymphokines/metabolism | 2 | 0.0 |
Microscopy, Confocal | 6 | 0.0 |
Thromboplastin/metabolism | 31 | 39.0 |
Vascular Endothelial Growth Factor A | 26 | 0.0 |
Vascular Endothelial Growth Factors | 26 | 0.0 |
DNA/metabolism | 9 | 0.0 |
Factor VIIa/*pharmacology | 3 | 75.0 |
Keratinocytes/*metabolism | 2 | 2.0 |
Mitogen-Activated Protein Kinase 3 | 7 | 1.0 |
Mitogen-Activated Protein Kinases/physiology | 2 | 1.0 |
Promoter Regions (Genetics) | 12 | 0.0 |
Thromboplastin/*physiology | 31 | 88.0 |
Trans-Activation (Genetics) | 3 | 0.0 |
Cell Line, Tumor | 9 | 0.0 |
Gene Expression Regulation, Neoplastic | 4 | 0.0 |
Incidence | 2 | 0.0 |
Mice | 78 | 0.0 |
Mice, Nude | 7 | 0.0 |
Oligonucleotide Array Sequence Analysis | 4 | 0.0 |
Serine Endopeptidases/metabolism | 4 | 3.0 |
Survival Rate | 2 | 0.0 |
Transfection | 29 | 0.0 |
Antibodies, Monoclonal/*therapeutic use | 3 | 0.0 |
Binding Sites | 45 | 0.0 |
Blood Coagulation/drug effects | 21 | 18.0 |
Disease Models, Animal | 10 | 0.0 |
Thrombosis/drug therapy/*prevention & control | 2 | 100.0 |
Hemostasis | 9 | 8.0 |
Models, Chemical | 6 | 1.0 |
Thromboplastin/chemistry/*metabolism | 6 | 85.0 |
Mice, SCID | 6 | 0.0 |
Transgenes | 2 | 0.0 |
Tumor Cells, Cultured | 65 | 0.0 |
Antigens/*immunology | 3 | 3.0 |
Child, Preschool | 24 | 0.0 |
Circular Dichroism | 4 | 0.0 |
Heat | 5 | 0.0 |
Gene Therapy/*methods | 2 | 0.0 |
Gene Transfer Techniques | 2 | 0.0 |
In Situ Nick-End Labeling | 2 | 0.0 |
Liposomes | 8 | 2.0 |
Neoplasm Transplantation | 7 | 0.0 |
Staining and Labeling/methods | 2 | 1.0 |
Transplantation, Heterologous | 3 | 0.0 |
Alleles | 24 | 0.0 |
Blood Group Antigens/*genetics | 11 | 10.0 |
Chi-Square Distribution | 4 | 0.0 |
Cluster Analysis | 3 | 1.0 |
Ethnic Groups/*genetics | 10 | 5.0 |
Gene Frequency | 45 | 0.0 |
Haplotypes | 7 | 0.0 |
Phenotype | 52 | 0.0 |
*Polymorphism, Genetic | 23 | 0.0 |
Coronary Circulation/*physiology | 2 | 20.0 |
Hemostasis/*physiology | 7 | 12.0 |
Models, Animal | 3 | 1.0 |
*Models, Biological | 7 | 3.0 |
Treatment Outcome | 11 | 0.0 |
Myocardium/metabolism | 3 | 1.0 |
Radiopharmaceuticals/diagnostic use/pharmacokinetics | 2 | 8.0 |
Reproducibility of Results | 13 | 0.0 |
Lymphatic Metastasis | 6 | 0.0 |
Neoplasm Invasiveness | 6 | 0.0 |
Neoplasm Staging | 11 | 0.0 |
Neovascularization, Pathologic/*metabolism | 4 | 3.0 |
Thromboplastin/*analysis | 37 | 82.0 |
Drug Evaluation, Preclinical | 4 | 2.0 |
Fibrin/analysis | 2 | 6.0 |
Fibrinogen/analysis | 4 | 2.0 |
Gene Expression Regulation/*drug effects | 17 | 2.0 |
Kidney Glomerulus/chemistry | 2 | 22.0 |
Leukocytes/*metabolism | 3 | 3.0 |
Lipopolysaccharides/toxicity | 5 | 6.0 |
RNA, Messenger/*biosynthesis | 3 | 1.0 |
Blood Coagulation Factors/metabolism | 12 | 22.0 |
Cell Adhesion Molecules/blood | 2 | 6.0 |
Cross-Sectional Studies | 8 | 0.0 |
Renal Dialysis/adverse effects | 2 | 6.0 |
Thrombophilia/blood/*etiology | 2 | 22.0 |
Genes, Structural | 3 | 0.0 |
HLA Antigens/genetics | 2 | 0.0 |
Haplotypes/genetics | 3 | 0.0 |
Infant, Newborn | 16 | 0.0 |
Liver/metabolism | 8 | 0.0 |
*Membrane Proteins | 5 | 0.0 |
Molecular Weight | 12 | 0.0 |
Plasma | 3 | 4.0 |
Drug Synergism | 11 | 0.0 |
MAP Kinase Signaling System | 2 | 0.0 |
Factor VIIa/*antagonists & inhibitors/metabolism | 4 | 80.0 |
Protein Binding/genetics | 7 | 3.0 |
Protein Engineering | 2 | 2.0 |
Solubility | 17 | 1.0 |
Surface Plasmon Resonance | 7 | 3.0 |
*Immediate-Early Proteins | 2 | 0.0 |
Osmolar Concentration | 4 | 0.0 |
Plasminogen Activator Inhibitor 1/*metabolism | 2 | 9.0 |
Thromboplastin/*antagonists & inhibitors/metabolism | 9 | 90.0 |
Blood Coagulation Factors/drug effects/metabolism | 2 | 33.0 |
Thromboplastin/antagonists & inhibitors/metabolism | 2 | 66.0 |
Antineoplastic Agents/*pharmacology | 3 | 0.0 |
Arsenicals/*pharmacology | 4 | 15.0 |
Cycloheximide/pharmacology | 8 | 1.0 |
Dactinomycin/pharmacology | 7 | 2.0 |
Leukemia, Promyelocytic, Acute/*metabolism/pathology | 2 | 22.0 |
Oxides/*pharmacology | 4 | 17.0 |
Thromboplastin/*genetics | 23 | 79.0 |
Tretinoin/*pharmacology | 10 | 3.0 |
Endothelium, Vascular/cytology/*metabolism | 9 | 5.0 |
RNA, Messenger/*analysis | 3 | 0.0 |
U937 Cells | 5 | 1.0 |
Catalysis | 14 | 1.0 |
Factor VIIa/chemistry/*metabolism | 4 | 100.0 |
Hydrogen-Ion Concentration | 15 | 1.0 |
Hydrolysis | 14 | 1.0 |
Recombinant Proteins/chemistry/metabolism | 9 | 1.0 |
Calibration | 2 | 1.0 |
Polymerase Chain Reaction/methods | 6 | 0.0 |
Quality Control | 3 | 1.0 |
Thromboplastin/*analysis/genetics | 3 | 60.0 |
Cohort Studies | 5 | 0.0 |
Follow-Up Studies | 16 | 0.0 |
Catalytic Domain | 3 | 1.0 |
Crystallography, X-Ray | 11 | 1.0 |
Epidermal Growth Factor/chemistry | 2 | 3.0 |
Hydrogen Bonding | 2 | 1.0 |
Models, Biological | 17 | 0.0 |
Models, Molecular | 26 | 0.0 |
Protein Conformation | 25 | 0.0 |
Protein Structure, Tertiary | 18 | 0.0 |
Fibrin/metabolism | 15 | 24.0 |
P-Selectin/physiology | 2 | 25.0 |
Thromboplastin/antagonists & inhibitors/physiology | 2 | 100.0 |
*Gene Therapy | 2 | 0.0 |
*Gene Transfer Techniques | 3 | 0.0 |
Particle Size | 4 | 1.0 |
Transferrin/*chemistry | 4 | 66.0 |
Cytokines/*physiology | 2 | 1.0 |
Endothelium, Vascular/pathology | 2 | 1.0 |
Infant | 14 | 0.0 |
Interleukin-6/blood | 3 | 0.0 |
Nitrates/blood | 2 | 7.0 |
Nitrites/blood | 2 | 8.0 |
Prospective Studies | 15 | 0.0 |
Fibrinolytic Agents/*pharmacology | 6 | 19.0 |
Plasminogen Activator Inhibitor 1/metabolism | 3 | 6.0 |
Signal Transduction | 11 | 0.0 |
Thrombin/metabolism | 6 | 4.0 |
Blotting, Northern | 23 | 0.0 |
Dose-Response Relationship, Drug | 47 | 0.0 |
Nitric-Oxide Synthase/antagonists & inhibitors | 2 | 4.0 |
Thrombin/*physiology | 2 | 9.0 |
Endothelium, Vascular/cytology/metabolism | 2 | 1.0 |
Interleukin-1/*pharmacology | 2 | 0.0 |
RNA, Messenger/drug effects/metabolism | 2 | 1.0 |
Rats | 37 | 0.0 |
Rats, Sprague-Dawley | 7 | 0.0 |
Thromboplastin/genetics/metabolism | 3 | 75.0 |
Umbilical Veins/cytology | 10 | 3.0 |
Up-Regulation/*drug effects | 3 | 4.0 |
Lung Neoplasms/secondary | 2 | 2.0 |
*Neoplasm Metastasis | 2 | 2.0 |
Receptors, Thrombin/*physiology | 2 | 20.0 |
Homeostasis/*physiology | 2 | 4.0 |
Japan | 2 | 0.0 |
Myocardial Infarction/*blood/etiology | 2 | 25.0 |
Plasminogen Activator Inhibitor 1/blood/physiology | 2 | 100.0 |
Risk Factors | 17 | 0.0 |
Antibodies/immunology | 3 | 0.0 |
CHO Cells | 10 | 0.0 |
Cell Compartmentation | 6 | 1.0 |
Endocytosis/*physiology | 5 | 4.0 |
Fluorescent Antibody Technique | 18 | 0.0 |
Hamsters | 16 | 0.0 |
Hela Cells | 7 | 0.0 |
Microscopy, Fluorescence | 3 | 0.0 |
Transferrin/metabolism | 14 | 8.0 |
Blood Coagulation Tests | 11 | 5.0 |
Factor VIIa/metabolism/*pharmacology | 5 | 83.0 |
Hemophilia A/*blood | 2 | 14.0 |
Hemophilia B/blood | 2 | 40.0 |
Thrombin/biosynthesis | 9 | 22.0 |
Organophosphorus Compounds/*diagnostic use | 6 | 42.0 |
Organotechnetium Compounds/*diagnostic use | 6 | 25.0 |
Radiopharmaceuticals/*diagnostic use | 2 | 4.0 |
Tomography, Emission-Computed, Single-Photon/*methods | 2 | 15.0 |
Mice, Inbred C3H | 4 | 0.0 |
Mice, Inbred C57BL | 12 | 0.0 |
Mice, Transgenic | 7 | 0.0 |
Recombinant Fusion Proteins/physiology | 2 | 0.0 |
Transferrin/genetics | 14 | 28.0 |
Binding, Competitive | 17 | 0.0 |
Chromatography, Gel | 9 | 1.0 |
Ligands | 13 | 0.0 |
Macromolecular Substances | 13 | 0.0 |
Mutation/*genetics | 2 | 0.0 |
Thermodynamics | 4 | 1.0 |
Ultracentrifugation | 2 | 1.0 |
Gene Expression/*drug effects | 2 | 0.0 |
Neoplasm Proteins/genetics | 2 | 0.0 |
Oncogene Proteins, Fusion/genetics | 2 | 2.0 |
RNA, Messenger | 4 | 0.0 |
Thromboplastin/biosynthesis/*genetics | 8 | 72.0 |
Transcription, Genetic/drug effects | 13 | 2.0 |
Aqueous Humor/*metabolism | 2 | 9.0 |
Disease Progression | 11 | 0.0 |
Endothelial Growth Factors/pharmacology | 2 | 1.0 |
Endothelium, Vascular/drug effects/metabolism | 3 | 5.0 |
Enzyme-Linked Immunosorbent Assay | 46 | 1.0 |
Lymphokines/pharmacology | 3 | 1.0 |
*Genetic Markers | 12 | 3.0 |
*Heterozygote | 2 | 0.0 |
Antioxidants/*therapeutic use | 2 | 6.0 |
Biological Markers/blood | 22 | 1.0 |
Dietary Supplements | 2 | 2.0 |
Ferritin/*blood | 3 | 4.0 |
Iron/*blood | 2 | 5.0 |
Gene Expression Regulation, Leukemic/*drug effects | 4 | 11.0 |
Neoplasm Proteins/physiology | 2 | 3.0 |
Antineoplastic Agents/*therapeutic use | 2 | 0.0 |
Arsenicals/*therapeutic use | 2 | 33.0 |
Blood Coagulation Factors/analysis | 2 | 3.0 |
*Hemostasis | 11 | 8.0 |
Oxides/*therapeutic use | 2 | 28.0 |
Tretinoin/*therapeutic use | 2 | 9.0 |
Antibodies, Monoclonal/immunology/pharmacology | 2 | 2.0 |
Blood Platelets/*metabolism | 4 | 1.0 |
Lipopolysaccharides/metabolism/pharmacology | 3 | 16.0 |
Monocytes/drug effects/*metabolism | 13 | 10.0 |
P-Selectin/immunology/*metabolism | 2 | 66.0 |
Thromboplastin/immunology/*metabolism | 6 | 100.0 |
Calcium/metabolism | 12 | 0.0 |
Cyclosporine/pharmacology | 4 | 1.0 |
DNA-Binding Proteins/*metabolism | 3 | 0.0 |
Endothelium, Vascular/drug effects/*metabolism | 9 | 11.0 |
Enzyme Activation/drug effects | 8 | 0.0 |
Mitogen-Activated Protein Kinase 1/metabolism | 2 | 0.0 |
Transcription Factors/*metabolism | 7 | 0.0 |
Alzheimer Disease/*genetics/metabolism/physiopathology | 3 | 23.0 |
DNA Mutational Analysis | 3 | 0.0 |
Genetic Predisposition to Disease/genetics | 2 | 0.0 |
Genetic Screening | 2 | 0.0 |
Genotype | 11 | 0.0 |
Iron/*metabolism | 26 | 20.0 |
Polymorphism, Genetic/*genetics | 8 | 0.0 |
Chromatography, High Pressure Liquid | 13 | 0.0 |
Precipitin Tests | 4 | 0.0 |
Spectrum Analysis, Mass | 6 | 1.0 |
Yeasts | 2 | 2.0 |
Exercise Test | 2 | 0.0 |
Factor VII/metabolism | 14 | 35.0 |
Fibrin/*metabolism | 3 | 7.0 |
Monocytes/metabolism | 11 | 3.0 |
Signal Transduction/*physiology | 6 | 0.0 |
Thrombin/*metabolism | 6 | 7.0 |
Thromboplastin/biosynthesis/*physiology | 3 | 100.0 |
Endothelium, Vascular/*drug effects/*metabolism | 2 | 14.0 |
Interleukin-1/metabolism | 2 | 0.0 |
RNA, Messenger/genetics/metabolism | 10 | 0.0 |
Thromboxane A2/metabolism | 2 | 20.0 |
Blood Coagulation | 23 | 13.0 |
Coagulants/pharmacology | 3 | 60.0 |
Hemostasis/*drug effects | 3 | 4.0 |
Research Support, U.S. Gov't, Non-P.H.S. | 36 | 0.0 |
Blood Platelets/*physiology | 7 | 4.0 |
Cell Communication | 6 | 2.0 |
Gene Expression Regulation | 9 | 0.0 |
Tumor Necrosis Factor-alpha/antagonists & inhibitors | 2 | 3.0 |
Thromboplastin/antagonists & inhibitors/*physiology | 4 | 100.0 |
Factor Xa/antagonists & inhibitors | 8 | 17.0 |
Thrombophilia/*blood/etiology | 2 | 40.0 |
Acute Disease | 13 | 0.0 |
Leukocyte Count | 9 | 0.0 |
RNA, Messenger/blood | 3 | 5.0 |
Antibodies/pharmacology | 7 | 1.0 |
Factor VIIa/metabolism | 23 | 46.0 |
Thromboplastin/immunology/*isolation & purification/metabolism | 2 | 100.0 |
Amino Acids/chemistry | 2 | 1.0 |
Blood Coagulation/physiology | 17 | 29.0 |
Endothelium, Vascular/metabolism | 7 | 2.0 |
Sepsis/blood | 2 | 18.0 |
Sequence Alignment | 10 | 0.0 |
Sequence Homology, Amino Acid | 7 | 0.0 |
Structure-Activity Relationship | 18 | 0.0 |
Thromboplastin/physiology | 6 | 37.0 |
Cells, Cultured/drug effects/metabolism | 7 | 16.0 |
Endothelium, Vascular/*drug effects/metabolism | 7 | 12.0 |
Lipopolysaccharides/*toxicity | 3 | 5.0 |
Rats, Wistar | 5 | 0.0 |
Aspartate Aminotransferases/blood | 2 | 1.0 |
Hemorrhage/etiology | 2 | 9.0 |
Partial Thromboplastin Time | 8 | 4.0 |
Platelet Count | 4 | 0.0 |
Thromboembolism/etiology | 3 | 20.0 |
Thrombomodulin/*blood | 3 | 11.0 |
Antithrombins/pharmacology | 3 | 25.0 |
*Equipment Failure Analysis | 2 | 66.0 |
Platelet Activation/*drug effects | 2 | 3.0 |
Cell Polarity | 3 | 2.0 |
Dogs | 5 | 0.0 |
*Endocytosis | 6 | 3.0 |
Epithelium/metabolism | 3 | 0.0 |
Kidney/metabolism | 3 | 0.0 |
Receptors, Cell Surface/*physiology | 2 | 0.0 |
Monocytes/cytology/*drug effects/metabolism | 2 | 20.0 |
Nitric Oxide/physiology | 2 | 4.0 |
Thromboplastin/drug effects/metabolism | 3 | 50.0 |
Thromboxane B2/metabolism | 2 | 9.0 |
Regional Blood Flow/physiology | 2 | 4.0 |
Thromboplastin/*biosynthesis | 59 | 80.0 |
Platelet Glycoprotein GPIIb-IIIa Complex/*antagonists & inhibitors | 3 | 15.0 |
Thrombelastography | 2 | 18.0 |
Peptide Library | 2 | 1.0 |
Recombinant Proteins/chemistry/genetics/metabolism | 7 | 2.0 |
Fibrinolysis/*physiology | 4 | 5.0 |
Platelet Aggregation/*physiology | 3 | 12.0 |
Fatty Acids, Monounsaturated/*pharmacology | 2 | 22.0 |
Hydroxymethylglutaryl-CoA Reductase Inhibitors/*pharmacology | 3 | 4.0 |
Indoles/*pharmacology | 2 | 2.0 |
Up-Regulation/drug effects | 10 | 2.0 |
Arteriosclerosis/prevention & control | 2 | 8.0 |
Cross-Over Studies | 2 | 0.0 |
Monocytes | 2 | 2.0 |
Thromboplastin/analysis/*metabolism | 2 | 100.0 |
Antibodies, Monoclonal/*immunology | 5 | 0.0 |
Antibody Specificity | 6 | 0.0 |
Glycosylation | 7 | 0.0 |
Life Tables | 2 | 1.0 |
Multivariate Analysis | 4 | 0.0 |
Protein Processing, Post-Translational | 2 | 0.0 |
Retrospective Studies | 6 | 0.0 |
Survival Analysis | 4 | 0.0 |
Tumor Markers, Biological/*analysis | 5 | 0.0 |
Genes | 2 | 0.0 |
In Situ Hybridization, Fluorescence | 2 | 0.0 |
Lod Score | 2 | 0.0 |
Phosphorylation/drug effects | 2 | 0.0 |
Cell Membrane/*metabolism | 5 | 1.0 |
Cell Culture Techniques | 2 | 0.0 |
Endothelium, Vascular/cytology/drug effects/*metabolism | 6 | 6.0 |
Heparin/pharmacology | 11 | 4.0 |
Iloprost/pharmacology | 2 | 22.0 |
Lipoproteins/metabolism | 5 | 4.0 |
Microscopy, Electron | 12 | 0.0 |
Thromboplastin/drug effects/*metabolism | 2 | 100.0 |
Animals, Newborn | 4 | 0.0 |
Fluorescein-5-isothiocyanate | 3 | 2.0 |
Fluorescent Dyes | 3 | 0.0 |
*Apoptosis | 4 | 0.0 |
Cell Membrane/drug effects/*metabolism | 2 | 13.0 |
Fibroblasts | 2 | 0.0 |
Neovascularization, Pathologic | 6 | 1.0 |
Thrombosis/*physiopathology | 3 | 37.0 |
Blood Pressure/physiology | 2 | 1.0 |
Computer Simulation | 4 | 1.0 |
Hemodynamic Processes/*physiology | 2 | 6.0 |
*Chromosome Deletion | 3 | 0.0 |
Enoxaparin/administration & dosage/pharmacology | 2 | 66.0 |
Heparin, Low-Molecular-Weight/administration & dosage/pharmacology | 2 | 50.0 |
Syndrome | 6 | 0.0 |
Antibodies, Monoclonal/immunology | 10 | 0.0 |
Antigens, Surface/*immunology | 2 | 1.0 |
Antigens, Tumor-Associated, Carbohydrate/*immunology | 3 | 15.0 |
HT29 Cells | 3 | 1.0 |
Age Factors | 8 | 0.0 |
Chromosome Mapping | 14 | 0.0 |
Sex Factors | 6 | 0.0 |
Homozygote | 5 | 0.0 |
Monocytes/*drug effects/metabolism | 21 | 21.0 |
Nitric Oxide Donors/pharmacology | 4 | 7.0 |
Platelet Aggregation Inhibitors/*pharmacology | 3 | 4.0 |
Promoter Regions (Genetics)/genetics | 5 | 0.0 |
TATA-Box Binding Protein | 3 | 0.0 |
Anti-Bacterial Agents/pharmacology | 3 | 2.0 |
Antigens, Tumor-Associated, Carbohydrate/*metabolism | 4 | 21.0 |
Carbohydrate Sequence | 10 | 3.0 |
Cell Differentiation/drug effects | 6 | 0.0 |
Cell Division/drug effects | 7 | 0.0 |
Colonic Neoplasms/immunology/*metabolism/pathology | 2 | 100.0 |
*Macrolides | 2 | 5.0 |
Coronary Circulation | 2 | 8.0 |
Factor Xa/metabolism | 16 | 29.0 |
Hemoglobins/*pharmacology | 3 | 42.0 |
Neoplasm Proteins/*biosynthesis/genetics | 4 | 2.0 |
Protein Synthesis Inhibitors/pharmacology | 6 | 1.0 |
Stimulation, Chemical | 5 | 1.0 |
Fibroblasts/metabolism | 3 | 0.0 |
Sheep | 2 | 0.0 |
Species Specificity | 13 | 0.0 |
Cell Membrane/metabolism/ultrastructure | 3 | 5.0 |
Iodine Radioisotopes/diagnostic use | 7 | 2.0 |
Iron/metabolism | 11 | 8.0 |
Microscopy, Immunoelectron | 3 | 0.0 |
Receptors, Transferrin/genetics/*metabolism | 2 | 25.0 |
Transferrin/*pharmacokinetics | 2 | 100.0 |
Endothelium, Vascular/cytology/*drug effects/metabolism | 10 | 11.0 |
Factor Xa/biosynthesis | 12 | 92.0 |
Promoter Regions (Genetics)/drug effects | 3 | 2.0 |
Regulatory Sequences, Nucleic Acid | 7 | 1.0 |
Surface Properties | 3 | 1.0 |
Transfection/*methods | 2 | 3.0 |
Factor VIIa/*chemistry/genetics/*metabolism | 2 | 100.0 |
Mutagenesis, Site-Directed | 13 | 0.0 |
Protein Structure, Secondary | 4 | 0.0 |
Variation (Genetics) | 6 | 0.0 |
Inflammation/metabolism | 2 | 2.0 |
Protein-Serine-Threonine Kinases/pharmacology | 2 | 18.0 |
Signal Transduction/drug effects | 10 | 1.0 |
Thromboplastin/*drug effects/genetics/metabolism | 2 | 100.0 |
Antithrombin III/analysis | 6 | 3.0 |
Peptide Hydrolases/analysis | 4 | 3.0 |
NF-kappa B/drug effects | 2 | 50.0 |
DNA/genetics | 9 | 0.0 |
*Gene Pool | 8 | 42.0 |
Russia | 6 | 6.0 |
Seasons | 2 | 1.0 |
Blood Coagulation Factors/*drug effects/metabolism | 2 | 66.0 |
Cell Adhesion/drug effects | 5 | 1.0 |
Lymphocyte Activation/drug effects | 7 | 1.0 |
Microspheres | 3 | 1.0 |
Thromboplastin/biosynthesis | 8 | 47.0 |
Binding Sites/genetics | 5 | 0.0 |
Conserved Sequence | 4 | 0.0 |
Iron-Binding Proteins | 5 | 35.0 |
Transferrin-Binding Proteins | 5 | 35.0 |
COS Cells | 2 | 0.0 |
Models, Genetic | 2 | 0.0 |
*Fibrinolysis | 3 | 2.0 |
Interleukin-1/blood | 2 | 1.0 |
Antifibrinolytic Agents/metabolism | 2 | 9.0 |
Fibrinogen/metabolism | 6 | 2.0 |
Linear Models | 3 | 0.0 |
Lipoproteins/*metabolism | 11 | 7.0 |
Lipoproteins/*analysis/blood | 2 | 40.0 |
Tissue Distribution | 7 | 0.0 |
Endarterectomy, Carotid | 2 | 15.0 |
Macrophages/pathology | 3 | 2.0 |
Ultrasonography, Doppler, Transcranial | 2 | 18.0 |
Allosteric Regulation/genetics | 3 | 75.0 |
Peptide Mapping | 3 | 0.0 |
*Saccharomyces cerevisiae Proteins | 3 | 0.0 |
*Transcription Factors, TFII | 4 | 3.0 |
Anticoagulants/metabolism | 2 | 11.0 |
Biopsy | 7 | 0.0 |
Double-Blind Method | 18 | 1.0 |
Tumor Necrosis Factor-alpha/administration & dosage/*pharmacology | 2 | 5.0 |
Regression Analysis | 5 | 0.0 |
Dose-Response Relationship, Immunologic | 4 | 0.0 |
Blood Proteins/analysis | 2 | 1.0 |
Cerebrospinal Fluid Proteins/analysis | 2 | 8.0 |
Specimen Handling | 2 | 2.0 |
Antineoplastic Combined Chemotherapy Protocols/*therapeutic use | 2 | 0.0 |
P-Glycoprotein/metabolism | 2 | 3.0 |
Predictive Value of Tests | 3 | 0.0 |
Radiopharmaceuticals/diagnostic use | 2 | 3.0 |
Arteriosclerosis/*metabolism/*pathology | 2 | 33.0 |
Cell Survival/drug effects | 5 | 0.0 |
Matrix Metalloproteinases/*metabolism | 2 | 5.0 |
Macrophages/metabolism | 4 | 1.0 |
NF-kappa B/antagonists & inhibitors/metabolism | 2 | 6.0 |
Peroxisome Proliferators/*pharmacology | 2 | 25.0 |
Pyrimidines/*pharmacology | 2 | 3.0 |
RNA, Messenger/antagonists & inhibitors | 3 | 14.0 |
Receptors, Cytoplasmic and Nuclear/*agonists | 2 | 11.0 |
Thromboplastin/*antagonists & inhibitors/genetics | 5 | 55.0 |
Transcription Factors/*agonists | 2 | 18.0 |
Antibodies, Monoclonal/pharmacology | 7 | 0.0 |
Protein Binding/drug effects | 5 | 1.0 |
Thromboplastin/genetics/immunology/*metabolism | 2 | 100.0 |
Hyperplasia | 3 | 0.0 |
Lipoproteins/*pharmacology | 12 | 27.0 |
NF-kappa B/*physiology | 2 | 2.0 |
Plasminogen Activator Inhibitor 1/*biosynthesis/genetics | 4 | 50.0 |
Gene Targeting | 3 | 0.0 |
Neoplasms/*blood | 2 | 4.0 |
Thromboplastin/*metabolism/physiology | 2 | 100.0 |
Tumor Markers, Biological/*blood | 4 | 0.0 |
Angioplasty, Transluminal, Percutaneous Coronary | 2 | 4.0 |
Biological Markers | 13 | 0.0 |
Coronary Angiography | 7 | 3.0 |
Umbilical Veins/metabolism | 4 | 12.0 |
Factor X/pharmacology | 3 | 60.0 |
Peptide Fragments/*metabolism | 3 | 2.0 |
Antibodies, Monoclonal/*pharmacology | 3 | 1.0 |
Anticoagulants/pharmacology | 6 | 8.0 |
Blood Flow Velocity | 2 | 2.0 |
Mutation/genetics | 3 | 0.0 |
Substrate Specificity | 9 | 0.0 |
Tetradecanoylphorbol Acetate/pharmacology | 16 | 0.0 |
Tumor Necrosis Factor-alpha/*pharmacology | 14 | 1.0 |
Muscle, Smooth, Vascular/cytology/drug effects/*metabolism | 2 | 7.0 |
Nitric Oxide/metabolism | 2 | 1.0 |
Nitric-Oxide Synthase/genetics/metabolism | 3 | 13.0 |
Alcoholism/*diagnosis | 2 | 100.0 |
Antigens/metabolism | 5 | 7.0 |
Culture Techniques | 3 | 0.0 |
Stress, Mechanical | 6 | 2.0 |
Lipopolysaccharides/metabolism | 2 | 1.0 |
Phagocytosis | 5 | 1.0 |
Antibodies, Anticardiolipin/blood | 2 | 7.0 |
Radioligand Assay | 2 | 0.0 |
Thrombin/*biosynthesis | 7 | 21.0 |
Graft Rejection | 2 | 1.0 |
Transplantation, Homologous | 2 | 0.0 |
*Biological Markers | 2 | 1.0 |
Endothelial Growth Factors/*metabolism | 2 | 0.0 |
Lymphokines/*metabolism | 2 | 0.0 |
P-Selectin/*metabolism | 3 | 14.0 |
Platelet Activation | 7 | 5.0 |
Peptide Fragments/*pharmacology | 2 | 1.0 |
Endothelial Growth Factors/*biosynthesis/genetics | 3 | 2.0 |
Lymphokines/*biosynthesis/genetics | 3 | 2.0 |
Exertion | 2 | 2.0 |
Hyperhomocysteinemia/complications/epidemiology | 2 | 100.0 |
Prevalence | 5 | 0.0 |
Molecular Structure | 3 | 0.0 |
Thrombosis/etiology/physiopathology | 3 | 75.0 |
Hemophilia A/*drug therapy | 2 | 40.0 |
Recombinant Proteins/*therapeutic use | 2 | 9.0 |
*Drug Resistance, Multiple | 2 | 1.0 |
*Drug Resistance, Neoplasm | 2 | 1.0 |
Peptide Fragments/chemistry/genetics/metabolism | 2 | 2.0 |
Serine Endopeptidases/genetics | 2 | 5.0 |
Lipoproteins/*analysis | 2 | 10.0 |
Endotoxins/pharmacology | 7 | 10.0 |
Factor VII/*antagonists & inhibitors/metabolism | 4 | 100.0 |
Thromboplastin/*drug effects | 2 | 100.0 |
p-Methoxy-N-methylphenethylamine/*pharmacology | 4 | 80.0 |
Administration, Oral | 4 | 0.0 |
Drug Stability | 4 | 1.0 |
Contraceptive Agents, Female/*adverse effects | 2 | 66.0 |
Biological Transport | 12 | 0.0 |
Transferrin/*physiology | 5 | 83.0 |
Blood | 6 | 3.0 |
Coculture Techniques | 7 | 1.0 |
Lipopolysaccharides | 5 | 4.0 |
Amides/metabolism | 4 | 26.0 |
Cross-Linking Reagents | 3 | 0.0 |
*DNA-Binding Proteins | 2 | 0.0 |
Factor VIIa/chemistry/metabolism | 3 | 75.0 |
Factor X/chemistry/*metabolism | 2 | 66.0 |
Saccharomyces cerevisiae/genetics | 2 | 0.0 |
Thromboplastin/*chemistry/genetics/metabolism | 3 | 100.0 |
Blood Coagulation Factors/biosynthesis | 2 | 20.0 |
Coronary Vessels | 3 | 10.0 |
*Platelet Activation | 3 | 2.0 |
Cell Communication/physiology | 2 | 2.0 |
Mice, Inbred BALB C | 16 | 0.0 |
Myocardium/*metabolism | 2 | 0.0 |
Sex Characteristics | 2 | 0.0 |
Animals, Genetically Modified | 2 | 0.0 |
Antihypertensive Agents/pharmacology | 3 | 6.0 |
Blood Pressure/drug effects | 2 | 0.0 |
Sulfonamides/*pharmacology | 2 | 4.0 |
Thromboplastin/*drug effects/metabolism | 4 | 100.0 |
Transcription Factor AP-1/drug effects/metabolism | 2 | 33.0 |
Fibrinolytic Agents/metabolism | 2 | 16.0 |
Serine Proteinase Inhibitors/metabolism | 2 | 25.0 |
Antibodies/*immunology | 2 | 1.0 |
Glycoproteins/*immunology | 3 | 3.0 |
*Promoter Regions (Genetics) | 4 | 0.0 |
Immunohistochemistry/methods | 5 | 0.0 |
Aorta/metabolism | 2 | 5.0 |
Aspirin/therapeutic use | 2 | 5.0 |
Carotid Arteries/metabolism/pathology | 2 | 40.0 |
Thromboplastin/antagonists & inhibitors/*metabolism | 4 | 80.0 |
Thrombosis/etiology | 9 | 14.0 |
Oxidation-Reduction/drug effects | 2 | 2.0 |
Culture Media/pharmacology | 2 | 2.0 |
Culture Media, Serum-Free | 2 | 0.0 |
Enzyme Inhibitors/*pharmacology | 2 | 0.0 |
Flavonoids/pharmacology | 2 | 0.0 |
Muscle, Smooth, Vascular/*drug effects/metabolism | 3 | 27.0 |
Naphthalenes/pharmacology | 4 | 5.0 |
Platelet-Derived Growth Factor/pharmacology | 2 | 1.0 |
Thrombin/pharmacology | 7 | 3.0 |
*Lymphocyte Activation | 7 | 0.0 |
Antigens/immunology | 4 | 2.0 |
Endothelium, Vascular/cytology/*immunology | 2 | 6.0 |
Immunoglobulins, Fab/immunology | 2 | 1.0 |
Protein C/*metabolism | 3 | 1.0 |
Aorta | 5 | 3.0 |
Recombinant Proteins/metabolism | 10 | 0.0 |
Blood Platelets/metabolism | 6 | 3.0 |
Factor Xa/*antagonists & inhibitors | 6 | 16.0 |
Lipoproteins/*blood/immunology | 2 | 40.0 |
Monocytes/immunology/*metabolism | 3 | 6.0 |
Concanavalin A/pharmacology | 2 | 0.0 |
Lymphocyte Culture Test, Mixed | 2 | 0.0 |
Polysaccharides/*pharmacology | 2 | 8.0 |
Endotoxemia/*blood | 2 | 20.0 |
*Gene Expression | 3 | 0.0 |
Peptide Fragments/analysis | 6 | 2.0 |
Prothrombin/analysis | 6 | 8.0 |
RNA, Messenger/*metabolism | 4 | 0.0 |
Thromboplastin/*genetics/metabolism | 6 | 75.0 |
Depression, Chemical | 2 | 1.0 |
Graft Survival | 2 | 0.0 |
Heart Transplantation | 2 | 5.0 |
Lipopolysaccharides/antagonists & inhibitors/pharmacology | 2 | 9.0 |
Angiotensin II/*pharmacology | 2 | 1.0 |
Inflammation/physiopathology | 4 | 7.0 |
Proto-Oncogene Proteins c-fos/genetics | 2 | 3.0 |
Receptor, Angiotensin, Type 1 | 3 | 2.0 |
Receptor, Angiotensin, Type 2 | 2 | 2.0 |
Allosteric Regulation | 3 | 4.0 |
Mutagenesis | 2 | 0.0 |
Thromboplastin/*chemistry/genetics/*metabolism | 4 | 100.0 |
Anticoagulants/*blood | 2 | 15.0 |
Endothelium, Vascular/physiopathology | 2 | 5.0 |
*Orthopedics | 2 | 100.0 |
DNA Primers | 12 | 0.0 |
Anticoagulants/blood | 3 | 17.0 |
Fibrinolytic Agents/blood | 2 | 16.0 |
*Signal Transduction | 5 | 0.0 |
Ions | 2 | 2.0 |
Fibrinolytic Agents/*administration & dosage | 2 | 16.0 |
Recombinant Proteins/administration & dosage | 3 | 3.0 |
Factor VIIa/*pharmacology/therapeutic use | 2 | 100.0 |
Hemostatics/*pharmacology | 3 | 23.0 |
Factor VIIa/metabolism/pharmacology | 2 | 66.0 |
Membrane Lipids/metabolism | 4 | 8.0 |
Phosphatidylserines/metabolism | 4 | 7.0 |
Peptide Fragments/chemistry | 2 | 1.0 |
Intercellular Adhesion Molecule-1/metabolism | 5 | 2.0 |
Nitric-Oxide Synthase/metabolism | 3 | 2.0 |
Perfusion | 2 | 0.0 |
Vascular Cell Adhesion Molecule-1/metabolism | 3 | 3.0 |
Factor VIIa/*metabolism/pharmacology | 3 | 100.0 |
Fibroblasts/*metabolism | 2 | 1.0 |
Hirudins/pharmacology | 5 | 26.0 |
Arteriosclerosis/*metabolism/pathology | 4 | 10.0 |
Blood Vessels/chemistry | 2 | 33.0 |
Factor VII/analysis | 4 | 13.0 |
In Situ Hybridization | 8 | 0.0 |
Enzyme Activation | 17 | 0.0 |
Factor VIIa/*metabolism | 28 | 71.0 |
Factor X/*metabolism | 9 | 37.0 |
Mice, Knockout | 6 | 0.0 |
E-Selectin/metabolism | 4 | 8.0 |
Tumor Necrosis Factor-alpha/metabolism/*pharmacology | 2 | 3.0 |
Arginine/pharmacology | 2 | 7.0 |
Endothelium, Vascular/*metabolism | 21 | 7.0 |
Microcirculation | 2 | 0.0 |
Nitric Oxide/*metabolism | 2 | 1.0 |
DNA, Complementary | 3 | 0.0 |
Factor VIIa/*physiology | 5 | 83.0 |
Gene Expression Regulation/*physiology | 4 | 1.0 |
RNA, Messenger/genetics | 10 | 0.0 |
Transcription, Genetic | 9 | 0.0 |
Chromatography | 2 | 1.0 |
Electrophoresis, Gel, Two-Dimensional | 4 | 1.0 |
Neoplasm Proteins/*pharmacology | 2 | 15.0 |
Electrophoresis, Capillary | 2 | 4.0 |
Paternity | 4 | 5.0 |
*Polymorphism, Single Nucleotide | 2 | 0.0 |
Sequence Analysis, DNA | 2 | 0.0 |
Annexin A5/analysis | 2 | 9.0 |
Cells, Cultured/cytology/metabolism/secretion | 2 | 100.0 |
Coronary Vessels/cytology | 2 | 14.0 |
Genes, bcl-2 | 2 | 1.0 |
LDL-Receptor Related Protein 1/metabolism | 2 | 50.0 |
Lipoproteins, LDL/*metabolism/pharmacology | 2 | 28.0 |
Muscle, Smooth, Vascular/cytology/*metabolism/secretion | 2 | 100.0 |
Myocytes, Smooth Muscle/*metabolism | 2 | 33.0 |
Phospholipids/metabolism | 11 | 5.0 |
Proto-Oncogene Proteins c-bcl-2/biosynthesis/genetics | 2 | 4.0 |
Thromboplastin/*secretion | 3 | 100.0 |
*Antiplasmin | 3 | 7.0 |
Fibrin Fibrinogen Degradation Products/analysis | 3 | 2.0 |
Renal Dialysis/*adverse effects | 5 | 3.0 |
Disease Susceptibility | 2 | 0.0 |
Endothelial Growth Factors/*blood | 2 | 0.0 |
Lymphokines/*blood | 2 | 0.0 |
Antitubercular Agents/therapeutic use | 2 | 6.0 |
Data Interpretation, Statistical | 2 | 0.0 |
Models, Theoretical | 2 | 1.0 |
*Phenotype | 2 | 0.0 |
Pneumonectomy | 3 | 15.0 |
Fluorescent Antibody Technique, Indirect | 3 | 0.0 |
Inflammation | 5 | 1.0 |
Interleukin-4/pharmacology | 2 | 0.0 |
Reverse Transcriptase Polymerase Chain Reaction/methods | 2 | 0.0 |
Blood Coagulation/drug effects/physiology | 3 | 25.0 |
Blood Platelets/physiology | 6 | 10.0 |
Lipoproteins/physiology | 6 | 66.0 |
Electrophoresis, Capillary/*methods | 4 | 12.0 |
DNA Primers/genetics | 5 | 0.0 |
DNA, Complementary/*genetics | 2 | 0.0 |
Guinea Pigs | 6 | 0.0 |
Thromboplastin/chemistry/*genetics/metabolism | 2 | 100.0 |
Angina, Unstable/blood/complications | 2 | 100.0 |
Blood Chemical Analysis/*methods | 2 | 18.0 |
Evaluation Studies | 5 | 0.0 |
Antigens, CD/analysis | 2 | 0.0 |
Clone Cells | 3 | 0.0 |
K562 Cells | 3 | 0.0 |
Staurosporine/pharmacology | 3 | 1.0 |
Antigens/blood | 4 | 7.0 |
Antithrombin III/metabolism | 3 | 2.0 |
Cell Survival | 4 | 0.0 |
Peptide Hydrolases/metabolism | 3 | 2.0 |
Lymphocyte Activation | 10 | 0.0 |
Reactive Oxygen Species/*physiology | 2 | 16.0 |
Protein Isoforms | 3 | 0.0 |
Thromboplastin/*urine | 2 | 100.0 |
Genetic Predisposition to Disease | 3 | 0.0 |
Binding Sites/physiology | 4 | 2.0 |
Detergents | 4 | 3.0 |
Recombinant Proteins/metabolism/pharmacology | 2 | 1.0 |
Factor Xa/antagonists & inhibitors/metabolism | 2 | 25.0 |
Protein Biosynthesis | 3 | 0.0 |
Proteins/genetics | 2 | 0.0 |
Recombinant Proteins/*biosynthesis | 2 | 5.0 |
Gene Expression Regulation/*genetics | 3 | 2.0 |
Up-Regulation/genetics | 3 | 3.0 |
Antigens, Neoplasm/*immunology | 3 | 1.0 |
Calcium/*pharmacology | 2 | 2.0 |
Forensic Medicine | 3 | 5.0 |
Immunoblotting | 11 | 0.0 |
Semen/*chemistry | 2 | 7.0 |
Transferrin/*analysis | 9 | 42.0 |
Cell Nucleus/metabolism | 6 | 0.0 |
Losartan/pharmacology | 2 | 6.0 |
Monocytes/*drug effects/*metabolism | 2 | 14.0 |
Antithrombin III/pharmacology | 4 | 44.0 |
Lipoproteins/pharmacology | 4 | 18.0 |
Thromboplastin/pharmacology | 3 | 23.0 |
Electrophoretic Mobility Shift Assay | 5 | 1.0 |
I-kappa B/metabolism | 2 | 2.0 |
Inflammation/*metabolism | 2 | 3.0 |
von Willebrand Factor/metabolism | 4 | 1.0 |
Lactoferrin/*metabolism | 2 | 10.0 |
Endothelium, Vascular/drug effects/*physiology | 3 | 5.0 |
Glycoside Hydrolases/metabolism | 2 | 6.0 |
*Mutation | 3 | 0.0 |
Sequence Deletion | 5 | 0.0 |
*Gene Expression Regulation, Neoplastic | 3 | 0.0 |
Stromal Cells/*physiology | 2 | 8.0 |
Down-Regulation/drug effects | 3 | 1.0 |
Lipoproteins, LDL/*pharmacology | 2 | 3.0 |
Antigens, CD40/*metabolism | 2 | 4.0 |
CD40 Ligand | 2 | 1.0 |
Biological Assay | 2 | 0.0 |
Membranes, Artificial | 2 | 2.0 |
*Phospholipids | 2 | 40.0 |
Lipoproteins/*biosynthesis | 4 | 30.0 |
Muscle, Smooth, Vascular/*metabolism | 5 | 10.0 |
*Smoking/adverse effects | 2 | 40.0 |
Antiphospholipid Syndrome/*blood | 3 | 42.0 |
Leukocytes, Mononuclear/*metabolism | 3 | 2.0 |
Apoptosis | 3 | 0.0 |
Combined Modality Therapy | 8 | 0.0 |
Antigens, CD/*physiology | 2 | 0.0 |
Cell Differentiation | 8 | 0.0 |
Growth Inhibitors/*pharmacology | 2 | 1.0 |
Interleukin-6/pharmacology | 2 | 0.0 |
Lymphokines/*pharmacology | 2 | 0.0 |
Macrophages/*metabolism | 3 | 1.0 |
Membrane Glycoproteins/*physiology | 2 | 0.0 |
Arteriosclerosis/*physiopathology | 3 | 17.0 |
Thrombosis/*etiology | 6 | 12.0 |
Antigens/analysis | 5 | 3.0 |
Factor VIIa/analysis | 2 | 33.0 |
Plasminogen Activator Inhibitor 1/analysis | 3 | 9.0 |
Chemistry, Physical | 5 | 3.0 |
Factor VIIa/*chemistry/metabolism | 4 | 100.0 |
Magnetic Resonance Spectroscopy | 4 | 0.0 |
Thromboplastin/*chemistry/metabolism | 3 | 100.0 |
Factor VII/physiology | 3 | 100.0 |
Monocytes/*physiology | 10 | 6.0 |
Fatty Acids, Omega-3/*pharmacology | 2 | 18.0 |
Nitric Oxide/biosynthesis | 2 | 2.0 |
Tumor Necrosis Factor-alpha/biosynthesis | 3 | 0.0 |
Body Mass Index | 3 | 0.0 |
Body Weight | 2 | 0.0 |
Monocytes/*chemistry | 2 | 13.0 |
Endothelium, Vascular/*physiology | 5 | 3.0 |
Umbilical Veins/*physiology | 2 | 100.0 |
Kidney Failure, Chronic/*blood | 2 | 3.0 |
Lipoproteins/biosynthesis | 5 | 35.0 |
*Renal Dialysis | 3 | 0.0 |
Endotoxins/*pharmacology | 6 | 7.0 |
Haplorhini | 3 | 1.0 |
Protein Kinase C/antagonists & inhibitors/*metabolism | 3 | 3.0 |
*Trans-Activation (Genetics) | 2 | 0.0 |
Cytoplasm/metabolism | 5 | 0.0 |
ABO Blood-Group System/genetics | 6 | 14.0 |
Genetic Markers | 20 | 0.0 |
Moldova | 2 | 66.0 |
Rh-Hr Blood-Group System/genetics | 5 | 17.0 |
Endopeptidases/metabolism | 2 | 1.0 |
Monocytes/cytology/*metabolism | 3 | 10.0 |
Peptide Fragments/metabolism | 4 | 1.0 |
Protein C/metabolism | 2 | 2.0 |
Protein Precursors/metabolism | 2 | 1.0 |
Prothrombin/metabolism | 5 | 6.0 |
Lipoproteins/blood | 7 | 1.0 |
Monocyte Chemoattractant Protein-1/*blood | 2 | 14.0 |
Plasmids/genetics | 4 | 0.0 |
Factor Xa/*metabolism | 4 | 18.0 |
Introns | 2 | 0.0 |
Nuclear Proteins/metabolism | 2 | 0.0 |
Cell Cycle/drug effects | 3 | 0.0 |
Interferon Type II/pharmacology | 5 | 0.0 |
Ionomycin/pharmacology | 2 | 0.0 |
Leukemia, Promyelocytic, Acute/*pathology | 3 | 14.0 |
Neoplasm Proteins/*biosynthesis/genetics/physiology | 2 | 13.0 |
Thromboplastin/*biosynthesis/genetics/physiology | 3 | 100.0 |
Heparin, Low-Molecular-Weight/pharmacology | 2 | 18.0 |
*Blood Coagulation/drug effects | 2 | 25.0 |
von Willebrand Factor/analysis | 8 | 2.0 |
Cell Count | 2 | 0.0 |
Cell Division | 10 | 0.0 |
Aorta/cytology | 2 | 2.0 |
Cytokines/pharmacology | 2 | 0.0 |
Anticoagulants/*metabolism | 4 | 12.0 |
Blood Coagulation Factors/*metabolism | 6 | 7.0 |
Cadaver | 2 | 0.0 |
Tissue Plasminogen Activator/metabolism | 4 | 10.0 |
*Gene Expression Regulation | 12 | 0.0 |
Culture Media, Conditioned | 3 | 0.0 |
Solanaceous Alkaloids/*pharmacology | 2 | 100.0 |
Arteries/injuries | 2 | 100.0 |
Coronary Thrombosis/physiopathology | 2 | 100.0 |
Autoradiography | 2 | 0.0 |
Staining and Labeling | 6 | 0.0 |
Endothelium, Vascular/cytology | 4 | 1.0 |
Sequence Analysis | 3 | 0.0 |
Endometrium/*physiology | 2 | 13.0 |
Drug Screening Assays, Antitumor | 2 | 0.0 |
Fibrinolysis/drug effects | 2 | 5.0 |
Crosses, Genetic | 2 | 0.0 |
Thromboplastin/deficiency/genetics/*physiology | 2 | 100.0 |
Lipoproteins, LDL/*metabolism | 2 | 1.0 |
Cyclosporine/*therapeutic use | 2 | 6.0 |
Transfer Factor/*therapeutic use | 33 | 89.0 |
HLA Antigens/*genetics | 2 | 0.0 |
Heterozygote | 9 | 0.0 |
Receptors, Transferrin/*genetics | 2 | 11.0 |
Risk Assessment | 2 | 0.0 |
Blood Pressure | 3 | 0.0 |
Platelet Aggregation | 2 | 1.0 |
Angina Pectoris/blood | 2 | 14.0 |
Fibrinolysis/physiology | 3 | 6.0 |
Cell Adhesion | 10 | 0.0 |
Blood Coagulation Factors | 4 | 44.0 |
Heparin/*administration & dosage | 2 | 6.0 |
Monocytes/physiology | 2 | 1.0 |
Lipid Peroxidation | 2 | 1.0 |
Monocytes/drug effects/*physiology | 2 | 5.0 |
Placebos | 2 | 0.0 |
Chemical Fractionation | 3 | 4.0 |
Blood Coagulation Factors/*analysis | 3 | 3.0 |
C-Reactive Protein/analysis | 3 | 0.0 |
Homocysteine/blood | 2 | 1.0 |
Rupture, Spontaneous | 3 | 15.0 |
Lipids/metabolism | 2 | 0.0 |
Recombinant Proteins | 10 | 1.0 |
Thrombosis/etiology/*prevention & control | 2 | 33.0 |
Amino Acids/analysis | 3 | 1.0 |
Hydrogen Peroxide/pharmacology | 2 | 0.0 |
Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization | 2 | 0.0 |
Biological Transport/drug effects | 3 | 1.0 |
Fibrinopeptide A/metabolism | 2 | 8.0 |
Monocytes/metabolism/*physiology | 2 | 50.0 |
Tumor Necrosis Factor-alpha/metabolism | 3 | 0.0 |
Transferrin/*analogs & derivatives/metabolism | 2 | 100.0 |
Factor VIIa/*chemistry/genetics/metabolism | 2 | 100.0 |
Software | 2 | 0.0 |
Endothelial Growth Factors/*metabolism/pharmacology | 2 | 10.0 |
Lymphokines/*metabolism/pharmacology | 2 | 7.0 |
T-Lymphocytes/*metabolism | 3 | 0.0 |
Transcription Factors/genetics/*metabolism | 2 | 0.0 |
Cell Membrane Permeability/drug effects | 2 | 3.0 |
Lectins/*pharmacology | 2 | 5.0 |
Lipoproteins, LDL/pharmacology | 3 | 7.0 |
Lipoproteins, VLDL/pharmacology | 2 | 12.0 |
Triglycerides/*metabolism | 2 | 2.0 |
Genes, Reporter | 2 | 0.0 |
Disseminated Intravascular Coagulation/*blood | 5 | 23.0 |
Serine Proteinase Inhibitors | 2 | 22.0 |
Rats, Inbred Lew | 2 | 0.0 |
Thrombosis/*metabolism | 2 | 28.0 |
Endothelium, Vascular/drug effects/*metabolism/ultrastructure | 2 | 50.0 |
Microscopy, Electron, Scanning | 2 | 0.0 |
Saphenous Vein | 2 | 12.0 |
Thrombomodulin/analysis | 3 | 10.0 |
Body Height | 2 | 1.0 |
Copper/blood | 2 | 8.0 |
Selenium/blood | 2 | 18.0 |
Superoxide Dismutase/blood | 2 | 4.0 |
Bucladesine/pharmacology | 3 | 1.0 |
Lysophosphatidylcholines/*pharmacology | 2 | 16.0 |
Neoplasm Proteins/*metabolism | 4 | 0.0 |
Organophosphorus Compounds/diagnostic use/*pharmacokinetics | 2 | 100.0 |
Organotechnetium Compounds/diagnostic use/*pharmacokinetics | 2 | 66.0 |
P-Glycoprotein/*metabolism | 2 | 2.0 |
Radiopharmaceuticals/diagnostic use/*pharmacokinetics | 2 | 50.0 |
Antigens, CD40/*physiology | 2 | 5.0 |
Hemostasis/physiology | 3 | 9.0 |
Pyrrolidines/pharmacology | 2 | 4.0 |
Thiocarbamates/pharmacology | 2 | 3.0 |
Thromboplastin/*analysis/physiology | 4 | 80.0 |
Random Allocation | 8 | 1.0 |
DNA Primers/chemistry | 2 | 0.0 |
T-Lymphocytes/immunology | 11 | 0.0 |
Energy Metabolism/physiology | 2 | 3.0 |
Amino Acid Chloromethyl Ketones/pharmacology | 3 | 2.0 |
Monocytes/*drug effects | 5 | 9.0 |
Models, Statistical | 2 | 1.0 |
Thrombin/physiology | 3 | 8.0 |
Receptors, Transferrin/*immunology/metabolism | 3 | 100.0 |
Endothelial Growth Factors/*biosynthesis | 3 | 1.0 |
Lymphokines/*biosynthesis | 2 | 0.0 |
Pentoxifylline/*pharmacology | 3 | 8.0 |
Interleukin-10/*pharmacology | 3 | 3.0 |
Interleukin-4/*pharmacology | 5 | 2.0 |
Bronchoalveolar Lavage Fluid/*cytology | 2 | 4.0 |
Statistics, Nonparametric | 6 | 0.0 |
Factor VII/*metabolism | 9 | 40.0 |
Gene Expression Regulation, Bacterial | 3 | 5.0 |
Iron Radioisotopes | 2 | 66.0 |
Receptors, Transferrin/analysis/*metabolism | 2 | 100.0 |
Hemostatics/pharmacology | 2 | 8.0 |
Thromboplastin/*biosynthesis/drug effects | 5 | 83.0 |
Enzyme Tests | 2 | 2.0 |
Transferrin/analysis | 8 | 9.0 |
alpha-Fetoproteins/analysis | 2 | 0.0 |
Digoxigenin | 2 | 22.0 |
Thrombin/antagonists & inhibitors | 2 | 8.0 |
Birth Weight | 3 | 1.0 |
*Erythropoiesis | 2 | 2.0 |
Receptors, Transferrin/*blood | 2 | 14.0 |
Thromboplastin/biosynthesis/genetics | 3 | 75.0 |
Urinary Plasminogen Activator/biosynthesis/genetics | 2 | 40.0 |
Anticoagulants/therapeutic use | 2 | 2.0 |
Amino Acid Substitution/genetics | 2 | 0.0 |
Epidermal Growth Factor/*chemistry | 2 | 3.0 |
*Protein Structure, Tertiary | 2 | 1.0 |
Emigration and Immigration | 2 | 4.0 |
Gene Frequency/*genetics | 2 | 1.0 |
India | 6 | 1.0 |
Selection (Genetics) | 2 | 1.0 |
Infusions, Intravenous | 4 | 0.0 |
Ammonium Compounds/pharmacology | 2 | 8.0 |
Ferric Compounds/pharmacology | 2 | 18.0 |
Isoelectric Point | 3 | 2.0 |
Injections, Intravenous | 2 | 0.0 |
Water | 3 | 5.0 |
Antithrombins/analysis | 2 | 12.0 |
Endothelium, Vascular/*pathology | 4 | 6.0 |
Protein C/analysis | 2 | 3.0 |
Thrombomodulin/blood | 3 | 8.0 |
*Databases, Genetic | 2 | 22.0 |
Internet | 2 | 2.0 |
Calcimycin/pharmacology | 2 | 0.0 |
Epithelial Cells/metabolism | 2 | 0.0 |
Blood Cells/metabolism | 2 | 6.0 |
Transcription Factor TFIID | 2 | 1.0 |
Chromatography, Affinity/*methods | 2 | 8.0 |
Enzyme-Linked Immunosorbent Assay/methods | 3 | 1.0 |
Hemorheology | 4 | 12.0 |
NG-Nitroarginine Methyl Ester/pharmacology | 3 | 6.0 |
Antibodies, Monoclonal | 10 | 0.0 |
Biosensing Techniques | 2 | 3.0 |
Epitope Mapping | 3 | 1.0 |
Albumins/pharmacology | 2 | 22.0 |
Antioxidants/pharmacology | 2 | 1.0 |
Oxidative Stress/*physiology | 3 | 3.0 |
Calcium/*metabolism | 5 | 0.0 |
Indoles/pharmacology | 3 | 1.0 |
Maleimides/pharmacology | 2 | 2.0 |
CD40 Ligand/*blood | 2 | 33.0 |
Interleukin-6/*blood | 3 | 1.0 |
Platelet Aggregation Inhibitors/therapeutic use | 2 | 7.0 |
Drug Antagonism | 2 | 4.0 |
Tumor Necrosis Factor-alpha/biosynthesis/genetics | 2 | 3.0 |
Plasminogen Activator Inhibitor 1/*biosynthesis | 4 | 36.0 |
Epitopes | 7 | 0.0 |
Models, Cardiovascular | 7 | 14.0 |
Transferrin-Binding Protein B | 2 | 40.0 |
Blood Group Antigens/genetics | 6 | 10.0 |
Demography | 3 | 2.0 |
European Continental Ancestry Group/genetics | 2 | 0.0 |
Polymorphism, Genetic | 21 | 0.0 |
Siberia | 5 | 12.0 |
*Cell Communication | 2 | 2.0 |
Endothelium, Vascular/*cytology | 3 | 1.0 |
Escherichia coli/metabolism | 4 | 1.0 |
*Polymorphism, Restriction Fragment Length | 2 | 0.0 |
Transferrin/*genetics | 19 | 38.0 |
Phosphatidylcholines/metabolism | 2 | 2.0 |
Medroxyprogesterone 17-Acetate/pharmacology | 2 | 6.0 |
Stromal Cells/*metabolism | 2 | 5.0 |
*Neovascularization, Pathologic | 2 | 0.0 |
Enzyme Precursors/*metabolism | 2 | 1.0 |
Free Radical Scavengers/pharmacology | 2 | 3.0 |
Thromboplastin/antagonists & inhibitors/*biosynthesis | 2 | 100.0 |
Neovascularization, Pathologic/*physiopathology | 2 | 2.0 |
Vascular Diseases/*etiology | 2 | 50.0 |
Factor VIIa/pharmacology | 2 | 40.0 |
*Protein Folding | 2 | 1.0 |
Sequence Homology | 2 | 0.0 |
Radioimmunoassay | 5 | 0.0 |
Plant Lectins | 2 | 4.0 |
Platelet-Derived Growth Factor/*pharmacology | 2 | 2.0 |
*Heart Transplantation | 3 | 3.0 |
Energy Transfer | 2 | 3.0 |
Drug Design | 2 | 0.0 |
Magnetic Resonance Imaging | 2 | 0.0 |
Thrombosis/blood | 2 | 10.0 |
Endotoxins/physiology | 2 | 40.0 |
RNA, Messenger/drug effects/genetics/metabolism | 2 | 2.0 |
Thromboplastin/drug effects/*genetics | 2 | 100.0 |
Genetic Vectors | 4 | 0.0 |
Neutrophils/physiology | 2 | 1.0 |
Transduction, Genetic | 2 | 0.0 |
Fibrinolytic Agents/*metabolism | 3 | 37.0 |
Arteriosclerosis/metabolism | 2 | 3.0 |
Thrombosis/metabolism | 2 | 16.0 |
Endothelium, Vascular/*drug effects | 2 | 3.0 |
Antigens, Bacterial/*immunology | 2 | 1.0 |
Blood Donors | 4 | 1.0 |
Cell Migration Inhibition | 12 | 11.0 |
Hypersensitivity, Delayed/immunology | 4 | 6.0 |
Rosette Formation | 5 | 1.0 |
Staphylococcus aureus/*immunology | 3 | 3.0 |
Transfer Factor/*immunology/pharmacology | 2 | 100.0 |
Liver Neoplasms/*metabolism/secondary | 2 | 33.0 |
Point Mutation | 3 | 0.0 |
Prothrombin/*metabolism | 2 | 6.0 |
Endopeptidases/*metabolism | 3 | 2.0 |
Methionine/metabolism | 2 | 1.0 |
*Oxidative Stress | 4 | 1.0 |
Papio | 4 | 2.0 |
Culture Media | 9 | 1.0 |
Monocytes/pathology/*physiology | 2 | 40.0 |
Muscle, Smooth, Vascular/cytology | 2 | 6.0 |
Phospholipids/physiology | 2 | 22.0 |
*Neovascularization, Physiologic | 2 | 1.0 |
Adenoviridae/genetics | 2 | 0.0 |
Factor VIIa/antagonists & inhibitors | 4 | 44.0 |
Gene Expression Regulation, Leukemic | 2 | 2.0 |
Karyotyping | 4 | 0.0 |
Fibroblast Growth Factor 1/*pharmacology | 2 | 10.0 |
*Transcription, Genetic | 4 | 0.0 |
Tumor Necrosis Factor-alpha/analysis | 3 | 0.0 |
HL-60 Cells | 3 | 0.0 |
Brain/metabolism | 2 | 0.0 |
*Partial Thromboplastin Time | 2 | 11.0 |
*Prothrombin Time | 2 | 10.0 |
Transcription Factor TFIIB | 2 | 2.0 |
Receptors, Cell Surface/physiology | 2 | 1.0 |
Hemoglobins/metabolism | 2 | 1.0 |
Lactoferrin/metabolism | 3 | 12.0 |
Drug Evaluation | 6 | 2.0 |
Edetic Acid/pharmacology | 3 | 1.0 |
Hypersensitivity, Delayed/*immunology | 4 | 11.0 |
Transfer Factor/*administration & dosage/immunology | 2 | 100.0 |
Thrombomodulin/*metabolism | 3 | 12.0 |
Transcription Factor, Sp1/metabolism | 2 | 0.0 |
Antithrombin III/*pharmacology | 2 | 33.0 |
Blood Cell Count | 2 | 0.0 |
Nephelometry and Turbidimetry | 2 | 2.0 |
Cholesterol/metabolism | 2 | 0.0 |
Proto-Oncogene Proteins c-rel | 2 | 3.0 |
Antithrombin III/*metabolism | 2 | 3.0 |
Factor IX/metabolism | 5 | 35.0 |
Phospholipids/pharmacology | 3 | 9.0 |
Plasminogen Activator Inhibitor 2/*biosynthesis/genetics | 2 | 100.0 |
Histocytochemistry | 5 | 0.0 |
Indicators and Reagents | 4 | 1.0 |
Immunoelectrophoresis | 3 | 1.0 |
Receptors, Transferrin/*metabolism | 6 | 26.0 |
Transferrin/isolation & purification/*metabolism | 2 | 100.0 |
Hemorrhage/*etiology | 2 | 22.0 |
Receptors, Cell Surface/*metabolism | 5 | 0.0 |
Complement 3/genetics | 6 | 16.0 |
*Gene Frequency | 12 | 2.0 |
Blood Protein Electrophoresis | 2 | 1.0 |
Liver Function Tests | 2 | 1.0 |
Transferrin/*analogs & derivatives/*metabolism | 2 | 100.0 |
Aspirin/*pharmacology | 2 | 4.0 |
NF-kappa B/*metabolism | 2 | 0.0 |
Thromboplastin/analysis/*genetics | 2 | 100.0 |
Collagen/pharmacology | 3 | 2.0 |
Factor VIII/physiology | 2 | 22.0 |
Factor XI Deficiency/blood | 2 | 100.0 |
Feedback, Biochemical | 2 | 4.0 |
Hemophilia A/blood | 3 | 18.0 |
Cell Movement | 2 | 0.0 |
Receptor, PAR-2/*metabolism | 2 | 66.0 |
Coronary Arteriosclerosis/*etiology | 2 | 40.0 |
Macrophages/*drug effects/metabolism | 3 | 8.0 |
Fluorescence | 2 | 0.0 |
Hematologic Diseases/*blood | 3 | 30.0 |
Pregnancy/*blood | 2 | 1.0 |
Diabetes Mellitus/*blood | 2 | 2.0 |
Pilot Projects | 5 | 0.0 |
Blood Proteins/*genetics | 15 | 9.0 |
Genetic Markers/*genetics | 3 | 2.0 |
*Genetics, Population | 19 | 5.0 |
Epithelial Cells | 2 | 0.0 |
Fibrinolysis/*drug effects | 3 | 4.0 |
Genistein | 2 | 2.0 |
Inflammation Mediators/*pharmacology | 2 | 12.0 |
Isoflavones/pharmacology | 2 | 3.0 |
Urinary Plasminogen Activator/metabolism | 4 | 9.0 |
Thrombosis/*blood | 3 | 10.0 |
Transforming Growth Factor beta/*pharmacology | 2 | 0.0 |
Breast Neoplasms/*chemistry/pathology | 2 | 3.0 |
Transferrin/*pharmacology | 5 | 38.0 |
Genetic Markers/genetics | 4 | 0.0 |
*Variation (Genetics) | 6 | 0.0 |
Cross Reactions | 4 | 0.0 |
Cholesterol/blood | 2 | 0.0 |
Hyperlipidemia/*blood | 2 | 5.0 |
Cercopithecus aethiops | 2 | 0.0 |
*Caveolins | 2 | 5.0 |
Membrane Glycoproteins/metabolism | 2 | 0.0 |
Membrane Proteins/metabolism | 4 | 0.0 |
ABO Blood-Group System | 2 | 3.0 |
Lectins | 3 | 3.0 |
Organ Specificity | 4 | 0.0 |
*Plant Lectins | 2 | 1.0 |
*Protein Conformation | 3 | 1.0 |
Spectrophotometry, Ultraviolet | 2 | 1.0 |
Apoproteins/metabolism | 3 | 18.0 |
Serum Albumin/pharmacology | 2 | 5.0 |
Tissue Donors | 2 | 0.0 |
Homeostasis | 4 | 1.0 |
Menstruation/*physiology | 2 | 28.0 |
Plasminogen Activator Inhibitor 1/biosynthesis | 3 | 27.0 |
Tissue Plasminogen Activator/biosynthesis | 4 | 26.0 |
Urinary Plasminogen Activator/biosynthesis | 2 | 20.0 |
Antigen-Antibody Reactions | 3 | 0.0 |
Cell Line, Transformed | 3 | 0.0 |
Bacterial Proteins/metabolism | 2 | 3.0 |
Iron Chelating Agents/pharmacology | 2 | 8.0 |
Haptoglobins/genetics | 8 | 16.0 |
Vitamin D-Binding Protein/genetics | 4 | 14.0 |
Drug Carriers | 2 | 1.0 |
Transferrin/*chemistry/metabolism | 2 | 28.0 |
Biological Markers/analysis | 3 | 0.0 |
Iodine Radioisotopes | 2 | 0.0 |
C-Reactive Protein/metabolism | 3 | 1.0 |
Electrophoresis | 2 | 0.0 |
Cell Fractionation | 2 | 0.0 |
Annexin A5/pharmacology | 2 | 5.0 |
DNA/analysis | 2 | 0.0 |
Thromboplastin/*biosynthesis/metabolism | 2 | 100.0 |
Buffers | 2 | 1.0 |
Horses | 3 | 2.0 |
Chronic Disease | 6 | 0.0 |
Tumor Cells, Cultured/drug effects | 3 | 0.0 |
Tumor Stem Cells/*drug effects/metabolism | 2 | 22.0 |
Culture Media, Conditioned/pharmacology | 2 | 1.0 |
Leukocytes/immunology | 7 | 5.0 |
Immunity, Cellular/drug effects/immunology | 8 | 47.0 |
Candida albicans/immunology | 4 | 9.0 |
Cytomegalovirus/immunology | 3 | 4.0 |
Transfer Factor/immunology/*therapeutic use | 5 | 100.0 |
Immunotherapy | 9 | 2.0 |
Longitudinal Studies | 2 | 0.0 |
Neoplasm Recurrence, Local | 2 | 0.0 |
Adjuvants, Immunologic/*therapeutic use | 3 | 3.0 |
Antiviral Agents/immunology/*therapeutic use | 2 | 100.0 |
Antigens, Fungal/immunology | 2 | 9.0 |
Candidiasis, Chronic Mucocutaneous/immunology/*therapy | 2 | 100.0 |
Herpesvirus 4, Human/immunology | 2 | 2.0 |
Gallium/*pharmacology | 2 | 100.0 |
Factor VII/*antagonists & inhibitors | 5 | 83.0 |
Fibrinolytic Agents/*therapeutic use | 2 | 8.0 |
Recombinant Proteins/therapeutic use | 2 | 0.0 |
Endothelium, Vascular/*metabolism/microbiology | 2 | 100.0 |
Brain/*metabolism | 4 | 0.0 |
Transferrin/biosynthesis/*genetics | 4 | 66.0 |
Cell Adhesion/physiology | 2 | 0.0 |
Aprotinin/pharmacology | 2 | 9.0 |
*Protein Structure, Secondary | 2 | 1.0 |
Saccharomyces cerevisiae | 2 | 0.0 |
*Mutagenesis, Site-Directed | 3 | 3.0 |
Enzymes/genetics | 3 | 9.0 |
Erythrocytes/*enzymology | 5 | 0.0 |
Europe | 2 | 0.0 |
European Continental Ancestry Group/*genetics | 2 | 0.0 |
*Hemorheology | 2 | 7.0 |
Half-Life | 3 | 0.0 |
Polyethylene Glycols | 2 | 2.0 |
Receptors, Transferrin/metabolism | 3 | 4.0 |
Blood Proteins/genetics | 5 | 8.0 |
Erythrocytes/enzymology | 8 | 2.0 |
Pyrrolidines/*pharmacology | 2 | 9.0 |
Thiocarbamates/*pharmacology | 2 | 15.0 |
Dexamethasone/pharmacology | 2 | 0.0 |
Umbilical Veins/cytology/drug effects/metabolism | 2 | 18.0 |
Chromogenic Compounds | 4 | 18.0 |
*Flow Cytometry | 2 | 1.0 |
Cations, Divalent | 2 | 2.0 |
*Liposomes | 2 | 5.0 |
Phosphatidylcholines | 2 | 5.0 |
Phosphatidylserines | 2 | 20.0 |
Cyclic AMP/*physiology | 2 | 2.0 |
Recombinant Fusion Proteins/biosynthesis/genetics | 2 | 2.0 |
Genetics, Population | 4 | 1.0 |
Disseminated Intravascular Coagulation/blood | 4 | 21.0 |
Synovial Fluid/chemistry | 2 | 9.0 |
Cell Adhesion Molecules/metabolism | 2 | 0.0 |
E-Selectin | 2 | 2.0 |
Colon/metabolism | 2 | 1.0 |
Antibodies | 4 | 0.0 |
Cytosol/metabolism | 2 | 0.0 |
Kidney/cytology/metabolism | 2 | 2.0 |
Thromboplastin/biosynthesis/*metabolism | 2 | 66.0 |
Antigens, CD14 | 3 | 1.0 |
Tetradecanoylphorbol Acetate/*pharmacology | 3 | 0.0 |
Image Processing, Computer-Assisted | 4 | 1.0 |
Acrylic Resins | 3 | 12.0 |
Response Elements/*genetics | 2 | 3.0 |
Endothelial Cells/drug effects/*metabolism | 2 | 25.0 |
Pentoxifylline/*therapeutic use | 2 | 9.0 |
Vasodilator Agents/*therapeutic use | 2 | 6.0 |
Antibodies, Monoclonal/diagnostic use | 8 | 0.0 |
Paraffin Embedding | 2 | 0.0 |
Glycosylphosphatidylinositols | 2 | 3.0 |
Factor VIIa | 3 | 75.0 |
Thromboplastin/*immunology/*metabolism | 2 | 100.0 |
Fibrin/physiology | 2 | 40.0 |
Cytokines/*pharmacology | 2 | 0.0 |
1-Methyl-3-isobutylxanthine/pharmacology | 2 | 2.0 |
Blood Proteins/*analysis | 2 | 1.0 |
RNA, Messenger/analysis/genetics | 3 | 0.0 |
Immunoassay | 2 | 0.0 |
Immunoelectrophoresis, Two-Dimensional | 2 | 1.0 |
Blood Coagulation Factors/physiology | 3 | 23.0 |
Binding Sites, Antibody | 4 | 1.0 |
Antibodies, Anticardiolipin/*immunology | 2 | 40.0 |
DNA Probes | 4 | 0.0 |
Ultrafiltration | 3 | 5.0 |
*Membrane Glycoproteins | 2 | 0.0 |
Exons | 2 | 0.0 |
Repetitive Sequences, Nucleic Acid | 2 | 0.0 |
Sequence Homology, Nucleic Acid | 3 | 0.0 |
RNA, Messenger/biosynthesis/metabolism | 2 | 4.0 |
Thromboplastin/analysis/*biosynthesis | 2 | 100.0 |
Diabetes Mellitus/blood | 2 | 2.0 |
Reference Standards | 2 | 0.0 |
Thromboplastin/*analysis/immunology | 3 | 100.0 |
Plasmids | 4 | 0.0 |
Transferrin/*biosynthesis/genetics | 2 | 100.0 |
Immunity, Cellular | 10 | 1.0 |
RNA, Messenger/*drug effects | 2 | 22.0 |
Protein Kinase C/physiology | 2 | 1.0 |
Liver/pathology | 2 | 1.0 |
Orosomucoid/metabolism | 2 | 9.0 |
Calcium/pharmacology | 2 | 0.0 |
Phosphatidylserines/pharmacology | 2 | 18.0 |
Arginine/metabolism | 2 | 3.0 |
Recombinant Proteins/genetics/metabolism | 2 | 0.0 |
Disseminated Intravascular Coagulation/*blood/etiology | 2 | 18.0 |
Protein Structure, Tertiary/genetics | 2 | 0.0 |
Receptors, Transferrin | 8 | 40.0 |
Factor VII/*pharmacology | 2 | 100.0 |
Peanut Agglutinin | 3 | 10.0 |
Sialic Acids/metabolism | 2 | 8.0 |
Transferrin/*analysis/chemistry | 2 | 100.0 |
Antibody Formation/drug effects | 2 | 4.0 |
Immunity, Cellular/drug effects | 4 | 6.0 |
*Isoelectric Focusing | 3 | 12.0 |
*Alleles | 8 | 0.0 |
RNA, Neoplasm/genetics | 2 | 0.0 |
Leukocyte Adherence Inhibition Test | 2 | 16.0 |
Lymphocytes/*immunology | 6 | 1.0 |
Skin Tests | 9 | 4.0 |
Transfer Factor/*pharmacology | 4 | 66.0 |
Tuberculin/*immunology | 2 | 11.0 |
Hypersensitivity, Delayed | 4 | 6.0 |
Lymphocytes/immunology | 6 | 1.0 |
Cardiopulmonary Bypass | 2 | 4.0 |
Oligopeptides/pharmacology | 2 | 1.0 |
RNA/genetics/isolation & purification | 3 | 2.0 |
Receptors, Thrombin | 4 | 8.0 |
Factor Xa/analysis | 3 | 75.0 |
Drug Resistance | 2 | 0.0 |
Transferrin/chemistry | 2 | 66.0 |
Endothelium, Vascular/*physiopathology | 2 | 2.0 |
Macrophages/drug effects/*physiology | 2 | 12.0 |
Protein Denaturation | 3 | 1.0 |
DNA | 2 | 0.0 |
African Continental Ancestry Group | 2 | 0.0 |
Asian Continental Ancestry Group | 3 | 1.0 |
European Continental Ancestry Group | 3 | 0.0 |
P-Selectin/blood | 2 | 3.0 |
Risk Assessment/methods | 2 | 7.0 |
Statistics | 4 | 0.0 |
Recombinant Proteins/*biosynthesis/genetics | 2 | 40.0 |
Linkage (Genetics) | 2 | 0.0 |
Estradiol/*pharmacology | 2 | 0.0 |
Rats, Inbred Strains | 5 | 0.0 |
Leukocytes/chemistry | 2 | 4.0 |
Niacinamide/*pharmacology | 3 | 30.0 |
Plasminogen Inactivators/metabolism | 2 | 12.0 |
*Antigens, Tumor-Associated, Carbohydrate | 6 | 33.0 |
Neoplasms/physiopathology | 2 | 12.0 |
Antibodies, Monoclonal/*diagnostic use | 2 | 0.0 |
Proportional Hazards Models | 2 | 0.0 |
Interferon Type II/*pharmacology | 2 | 0.0 |
alpha 1-Antitrypsin/*genetics | 2 | 7.0 |
Protease Inhibitors/*blood | 2 | 14.0 |
Blood Grouping and Crossmatching | 4 | 5.0 |
Georgia (Republic) | 3 | 42.0 |
ABO Blood-Group System/*genetics | 2 | 4.0 |
Clinical Trials | 12 | 1.0 |
Drug Combinations | 2 | 0.0 |
Transfer Factor/*administration & dosage | 3 | 100.0 |
*Chromosome Mapping | 6 | 0.0 |
Temperature | 3 | 0.0 |
Down-Regulation/genetics | 2 | 3.0 |
USSR | 5 | 27.0 |
Receptors, Transferrin/physiology | 2 | 25.0 |
Platelet Activation/drug effects | 2 | 3.0 |
South Africa | 2 | 1.0 |
Kidney Failure, Chronic/*blood/therapy | 2 | 3.0 |
Lung Neoplasms/*immunology | 2 | 4.0 |
T-Lymphocytes/*immunology | 4 | 0.0 |
Nucleic Acid Hybridization | 2 | 0.0 |
*Ethnic Groups | 7 | 6.0 |
*Genetics, Medical | 2 | 16.0 |
Geography | 2 | 3.0 |
Endothelial Growth Factors | 2 | 20.0 |
Tumor Necrosis Factor-alpha/genetics | 2 | 0.0 |
Transfer Factor/analysis/*immunology | 3 | 100.0 |
Thromboplastin/antagonists & inhibitors/biosynthesis/*physiology | 2 | 100.0 |
Trypsin | 2 | 1.0 |
Factor VII/therapeutic use | 2 | 100.0 |
Isoelectric Focusing/methods | 2 | 6.0 |
Estradiol/blood | 2 | 0.0 |
Anorexia Nervosa/blood | 2 | 25.0 |
Cushing Syndrome/blood | 2 | 40.0 |
Endocrine System Diseases/*blood | 2 | 40.0 |
Insulin-Like Growth Factor I/blood | 4 | 23.0 |
Transferrin/*blood | 3 | 100.0 |
*Lipoproteins | 4 | 11.0 |
Thromboplastin/antagonists & inhibitors | 2 | 28.0 |
Factor Xa | 3 | 15.0 |
Endothelial Cells/*metabolism | 2 | 6.0 |
Finland | 2 | 0.0 |
Transfer Factor/isolation & purification/*therapeutic use | 2 | 100.0 |
Disaccharides/*analysis | 2 | 66.0 |
Greece | 2 | 2.0 |
*Transferrin | 3 | 75.0 |
Mitogens/pharmacology | 2 | 0.0 |
Hela Cells/metabolism | 2 | 1.0 |
Iron Radioisotopes/diagnostic use | 2 | 22.0 |
*Linkage (Genetics) | 3 | 0.0 |
Immunoglobulin G/immunology | 4 | 1.0 |
B-Lymphocytes/immunology | 3 | 0.0 |
Immunoglobulins/analysis | 3 | 1.0 |
Transfer Factor/therapeutic use | 2 | 50.0 |
Pedigree | 3 | 0.0 |
Anticoagulants/administration & dosage | 3 | 21.0 |
Drug Therapy, Combination | 6 | 0.0 |
*Stents | 2 | 3.0 |
Brazil | 2 | 0.0 |
Indians, South American | 2 | 14.0 |
Freezing | 2 | 2.0 |
Congo | 2 | 40.0 |
Endocytosis | 3 | 0.0 |
Liver/*metabolism | 3 | 0.0 |
Phytohemagglutinins/pharmacology | 4 | 0.0 |
Cell Membrane/immunology | 2 | 0.0 |
Subcellular Fractions/metabolism | 2 | 0.0 |
Transferrin/analysis/*genetics | 5 | 71.0 |
Ethnic Groups | 3 | 1.0 |
Ferritin/*pharmacology | 2 | 66.0 |
Hematopoiesis/*drug effects | 2 | 2.0 |
Histocompatibility Antigens Class II/*immunology | 2 | 1.0 |
Lactoferrin/*pharmacology | 2 | 8.0 |
Lactoglobulins/*pharmacology | 3 | 37.0 |
Recombinant Proteins/*pharmacology | 3 | 3.0 |
Hemostasis/drug effects | 2 | 6.0 |
Collagen/metabolism | 2 | 0.0 |
Lung Neoplasms/radionuclide imaging/*secondary | 2 | 100.0 |
Electrophoresis, Agar Gel | 2 | 0.0 |
Italy | 3 | 0.0 |
*Genes | 2 | 0.0 |
Lung Neoplasms/mortality/surgery/*therapy | 2 | 100.0 |
Transfer Factor/administration & dosage/*therapeutic use | 2 | 100.0 |
Carrier Proteins/genetics | 4 | 1.0 |
Vitamin D-Binding Protein | 4 | 14.0 |
*Chromosomes, Human, 1-3 | 2 | 3.0 |
*Epitopes | 4 | 2.0 |
Tuberculin/immunology | 4 | 7.0 |
Transfer Factor/*isolation & purification | 3 | 100.0 |
Germany, West | 3 | 6.0 |
*Paternity | 2 | 2.0 |
Lipoproteins/blood/drug effects | 2 | 14.0 |
Thromboplastin/analysis/drug effects | 2 | 100.0 |
Cell Cycle | 2 | 0.0 |
Dialysis | 3 | 6.0 |
Gels | 2 | 2.0 |
Isoelectric Focusing/*methods | 3 | 8.0 |
Caspases/metabolism | 2 | 0.0 |
Transferrin/pharmacology | 3 | 11.0 |
Epithelial Cells/*physiology | 2 | 6.0 |
Recombination, Genetic | 2 | 0.0 |
*Cell Migration Inhibition | 3 | 7.0 |
*Receptors, G-Protein-Coupled | 2 | 0.0 |
*African Continental Ancestry Group | 2 | 1.0 |
Autoimmune Diseases/immunology | 2 | 2.0 |
Diphtheria Toxoid/immunology | 2 | 25.0 |
Macrophages/*immunology | 3 | 1.0 |
Transfer Factor/*immunology | 2 | 100.0 |
Tuberculin Test | 3 | 5.0 |
Skin/pathology | 2 | 0.0 |
Tuberculin | 2 | 20.0 |
Immunologic Techniques | 2 | 0.0 |
*Immunity, Cellular | 3 | 2.0 |
Immunologic Deficiency Syndromes/*drug therapy | 2 | 50.0 |
Fibrin/biosynthesis | 2 | 40.0 |
Streptodornase and Streptokinase/immunology | 2 | 50.0 |
*Transfer Factor | 2 | 100.0 |
Conserved Sequence/genetics | 2 | 1.0 |
Antigens | 3 | 3.0 |
Macrophages/immunology | 2 | 0.0 |
Immunosuppression | 2 | 1.0 |
Mitogens | 2 | 2.0 |
Leukemia/*blood | 2 | 15.0 |
Diagnosis, Differential | 2 | 0.0 |
Ophthalmoscopy/*methods | 2 | 100.0 |
Retina/*injuries/*pathology/physiopathology | 2 | 100.0 |
Retinal Diseases/classification/diagnosis/physiopathology | 2 | 66.0 |
Retinal Perforations/*classification/*pathology/physiopathology | 2 | 100.0 |
Tomography, Optical Coherence/*methods | 2 | 100.0 |
